Canagliflozin - Wikipedia

Canagliflozin (trade name Invokana or Sulisent) is a medication used for the treatment of type 2 diabetes. It is of the gliflozin class or subtype 2 sodium-glucose ...

Canagliflozin Nationwide Audit - Welcome to ABCD | ABCD ...

Above: Over 104 weeks canagliflozin use was associated with a significant reduction in weight compared to weight a increase associated with a ...

Selektive SGLT-2-inhibitorer og kombinationer

Selektive Sodium Glucose Co Transporter (SGLT)-2-inhibitorer er en stofgruppe, som selektivt og reversibelt hæmmer natrium-glucose cotransporter 2 i de proximale ...

FDA Reports Further Support for Canagliflozin-Amputation Link

The data are still insufficient to change prescribing recommendations, but they do suggest caution in prescribing canagliflozin for people at increased amputation risk.

CANVAS - CANagliflozin cardioVascular Assessment Study ...

The study will evaluate canagliflozin compared to placebo on CV events including CV death, heart attack, and stroke in patients with T2DM, whose diabetes is not well ...

INVOKANA® (canagliflozin) Treatment | HCP

Learn about a once daily treatment option that can help lower blood glucose in adults with type 2 diabetes. See full Prescribing & Safety Info, including Boxed Warning.

Treatment with INVOKANA® (canagliflozin)

Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info & Boxed Warning.

Canagliflozin Renal Outcomes Study Is Halted Early for ...

Hope that observed renoprotective effects of SGLT2 inhibitors will delay worsening of kidney disease in type 2 diabetes seems to be borne out, as the CREDENCE trial ...

Safety Information & Possible Side Effects: INVOKANA ...

Read Important Safety Information and discover possible INVOKANA® (canagliflozin) side effects. See full Prescribing & Safety Info, including Boxed Warning.

Canagliflozin and Cardiovascular and Renal Events in Type ...

Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes ...